In a child with congenital hyperinsulinism on diazoxide who recently contracted COVID‑19, how should severe reactive hypoglycemia be managed?

Management of Severe Reactive Hypoglycemia in a Child with Congenital Hyperinsulinism on Diazoxide Following COVID-19

Continue diazoxide therapy with intensified glucose monitoring (every 2-4 hours) and be prepared to increase the dose up to the maximum of 15 mg/kg/day in infants or 8 mg/kg/day in older children, while closely monitoring for COVID-19-related insulin resistance that may require substantially higher insulin counterregulation support. 1

Understanding the COVID-19 Connection

COVID-19 can directly affect pancreatic β-cells through ACE2 receptor expression, potentially worsening hyperinsulinism 2. The virus may cause:

• Direct β-cell dysfunction leading to paradoxical insulin dysregulation
• Marked insulin resistance disproportionate to typical critical illness 2
• New-onset or worsening glucose dysregulation even in previously stable patients 3, 2

This creates a particularly challenging scenario in congenital hyperinsulinism where the underlying excessive insulin secretion may be exacerbated by viral effects on pancreatic tissue.

Immediate Management Algorithm

Step 1: Intensify Monitoring

• Increase glucose monitoring to every 2-4 hours or implement continuous glucose monitoring 2
• Monitor for ketones in urine, especially during stress 1
• Check for signs of dehydration (COVID-19 increases this risk)

Step 2: Optimize Diazoxide Dosing

Do not stop diazoxide 2. Instead:

• If currently on doses <5 mg/kg/day, increase incrementally toward standard dosing
• Maximum doses: 15 mg/kg/day for infants, 8 mg/kg/day for older children 1
• Recent evidence shows even lower doses (2-3 mg/kg/day) can be effective in some cases, but severe reactive hypoglycemia warrants higher dosing 4
• Divide doses into 2-3 equal administrations per day 1

Step 3: Monitor for Diazoxide-Related Complications

Given COVID-19's effects on multiple organ systems, watch for:

• Fluid retention/edema (12% incidence) 4
• Hyponatremia (5% incidence) 4
• Pulmonary hypertension (2-3% risk, particularly concerning with COVID-19 respiratory involvement) 5
• Neutropenia (15% incidence) 5
• Renal function deterioration (COVID-19 can cause acute kidney injury) 2, 1

Step 4: Consider Additional Therapy if Diazoxide Insufficient

If hypoglycemia persists despite maximum diazoxide dosing:

Add octreotide as second-line therapy 6, 7, 8. Even patients with homozygous ABCC8 mutations (typically diazoxide-unresponsive) may respond to combination therapy 6.

• Start subcutaneous octreotide infusion at 5-10 µg/kg/day
• Can titrate up to 40 µg/kg/day 6
• Combination of diazoxide + octreotide may achieve euglycemia when either alone fails

Alternative option: Nifedipine has shown efficacy in isolated cases of diazoxide-resistant hyperinsulinism 7, though this is off-label and less well-studied.

Critical Pitfalls to Avoid

1. Do not discontinue diazoxide prematurely - Even partial responsiveness is valuable and should be maintained 6

2. Do not assume diazoxide failure without adequate trial - Some patients initially appearing unresponsive may respond with dose optimization or after acute illness resolves 6

3. Watch for dehydration - COVID-19 increases dehydration risk, which can precipitate lactic acidosis and worsen outcomes 2, 1

4. Monitor renal function closely - Diazoxide's half-life is prolonged in renal impairment, and COVID-19 can cause acute kidney injury 1

5. Do not overlook pulmonary complications - The combination of COVID-19 respiratory effects and diazoxide-associated pulmonary hypertension risk requires vigilant monitoring 5

Special Considerations for Post-COVID Context

The 2020 Lancet guidelines emphasize that all patients with COVID-19 and glucose dysregulation require continuous and reliable glycemic control 2. In your patient:

• COVID-19 may have triggered or worsened the reactive hypoglycemia through direct β-cell effects 2
• The tremendous insulin resistance observed in severe COVID-19 cases 2 creates a paradoxical situation in hyperinsulinism
• Long-term follow-up is essential as post-acute COVID-19 sequelae can persist for weeks to months 3

Genetic Testing Consideration

If not already performed, genetic testing should be pursued 9, 10. Knowing whether there is an underlying ABCC8/KCNJ11 mutation helps predict:

• Likelihood of diazoxide responsiveness
• Need for surgical evaluation (focal lesions are potentially curable)
• Long-term prognosis and spontaneous remission potential (66% in some series) 10

Importantly, spontaneous remission can occur even in severe cases and those with focal lesions 10, so aggressive surgical intervention should not be rushed in the acute post-COVID period unless medically refractory.